News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous02.03.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon Opening of review process guarantees reimbursement decision within next nine months Results of microsimulation model published in November 2019 show competitiveness […]

Read more

Epigenomics AG: Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

DGAP-News: Epigenomics AG / Key word(s): Study results/Study02.12.2019 / 11:37 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as […]

Read more

Epigenomics AG: New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

DGAP-News: Epigenomics AG / Key word(s): Study results/Study29.11.2019 / 15:00 The issuer is solely responsible for the content of this announcement. New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as decisive elements of successful screening strategies Berlin […]

Read more

Epigenomics AG Reports Financial Results for the First Nine Months 2019

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/9 Month figures19.11.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Nine Months 2019  Berlin (Germany) and San Diego, CA (USA), November 19, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) […]

Read more

Epigenomics AG Announces Conference Call with Authors Presenting at the European Public Health Conference

DGAP-News: Epigenomics AG / Key word(s): Scientific publication/Conference15.11.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Announces Conference Call with Authors Presenting at the European Public Health Conference   Berlin (Germany) and San Diego, CA (U.S.A.), November 15, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced […]

Read more

Epigenomics AG: No operational reasons for sharp decline in share price

DGAP-News: Epigenomics AG / Key word(s): Statement/Capital Increase 04.11.2019 / 20:55 The issuer is solely responsible for the content of this announcement. Epigenomics AG: No operational reasons for sharp decline in share price Berlin (Germany) and San Diego, CA (U.S.A.), 4 November, 2019 – The Epigenomics share price today recorded a decline of around 16% […]

Read more